In a world where scientific and medical dissent is marginalised, ridiculed or censored, we are very excited to be able to bring you, with our co-hosts at the Westreich Foundation, this almost 2 hour uncensored conversation chaired by a leading, highly published, US professor of family medicine and public health, Paul Mills PhD.
His guests are world leading cardiologist, Peter McCullough MD MPH FACC, vaccinologist, Geert Vanden Bossche DVM PhD, and our founder, Rob Verkerk MSc DIC PhD FACN. The topic of conversation was nothing less than some of the key issues around covid-19, mass vaccination and early treatment that have split societies all over the world.
This polarization now threatens social coherence and public trust in governments, health authorities and the medical establishment. Drivers include:
- high levels of inherent scientific uncertainty and complexity around the interactions between the SARS-CoV-2 virus and different population groups;
- the scale and rate of implementation of mass vaccination primarily under emergency use authorisations;
- subversion by health authorities of early treatment protocols with repurposed drugs and nutrients that have been shown to be clinically effective;
- the dynamic nature of SARS-CoV-2-human interactions, including the evolution of vaccine breakthrough variants with greater transmissibility;
- extreme censorship which prevents open scientific discourse and the development of true scientific consensus, and
- the creation of a lockstep narrative used by the mainstream media outlets that have been consistently shown, at given points in time, to not accurately reflect the state of existing knowledge on covid-19, its treatment or prevention.
As Professor of Family Medicine and Public Health at the University of California San Diego, Paul Mills’ mission was to tease from his guests information that would help viewers to better understand and unravel elements of the pandemic, and responses to it, especially those that run contrary to the direction of the mainstream narrative.